However, a risk of overcorrection of the APD to the point of triggering arrhythmia associated with the use of hERG activators exhibiting type 2 mechanism of actions has also been reported,14, 16, 30, 58 with this effect being concentration‐dependent.16, 24, 30. The gene discussed is KCNH2; the disease is Arrhythmia.